URAC Opioid Stewardship Designation — Frequently Asked Questions

Last updated: April 2026

Detailed answers to the most common questions about URAC's Opioid Stewardship Designation — what it is, who qualifies, what the four standards cover, how the review process works, and how it relates to your primary URAC accreditation. IHS is led by Thomas G. Goddard, JD, PhD, former Chief Operating Officer and General Counsel of URAC.

About the Designation

What is the URAC Opioid Stewardship Designation?

The URAC Opioid Stewardship Designation is an optional add-on designation developed by URAC to promote patient safety and the appropriate use of opioid medications, encourage innovation in opioid management, and decrease the risk of substance use disorder. It comprises four standards and supplements an existing URAC accreditation or certification — it is not a standalone program (URAC).

Applicants must hold or be actively pursuing an associated URAC program and must provide for or impact patient access to or use of opioid medications. The focused four-standard scope makes it one of the more streamlined URAC credentials to pursue — but each standard requires documented operational evidence, URAC-aligned policies, and staff training records.

Is the URAC Opioid Stewardship Designation an accreditation or a certification?

Neither. URAC formally categorizes it as a Designation — a distinct credential type within URAC's portfolio that supplements an existing accreditation or certification but does not stand alone. Organizations sometimes mischaracterize it as a certification. The correct and precise term is Designation. This distinction matters: URAC's reviewer training, evaluation criteria, and public directory placement differ for designations versus accreditations.

What are the four URAC Opioid Stewardship Designation standards?

URAC does not publicly publish the full standard text — the specific language and interpretive information are in URAC's purchasable standards documentation. Based on URAC's published program description, the four standards address:

• Promoting patient safety in opioid medication management
• Encouraging appropriate opioid use
• Fostering innovation in opioid management and monitoring
• Decreasing the risk of substance use disorder

Each standard carries URAC interpretive information that defines how compliance is evaluated in practice. The interpretive information — not just the standard text — governs what evidence URAC reviewers look for. This is where organizations without URAC-specific expertise consistently fall short.

What is a URAC Designation versus a URAC accreditation?

A URAC accreditation is a primary, standalone credential that evaluates an organization against a full standard set for a specific program. For example, URAC Specialty Pharmacy Accreditation covers pharmacy operations, quality management, patient safety, and staffing across a large standard set. A URAC Designation adds a focused set of standards to an existing accreditation, recognizing specialized competency in a defined area.

Other URAC designations include Measurement-Based Care, Integrated Behavioral Health, and Transitions of Care. All follow the same model: supplementary to a primary credential, not standalone.

Eligibility

Who is eligible for the URAC Opioid Stewardship Designation?

To be eligible, an organization must meet two criteria:

1. Hold or be actively pursuing recognition under an associated URAC program
2. Provide for or impact patient access to or use of opioid medications

Associated URAC programs span pharmacy programs (Specialty Pharmacy, Mail Service Pharmacy, Pharmacy Benefit Management, Workers' Compensation PBM), health plan programs, patient care management programs, and digital health and telehealth programs. Organizations operating exclusively outside the opioid medication pathway — for example, a URAC-accredited health utilization management organization with no pharmacy or opioid-related clinical programs — would not typically qualify.

Which types of organizations pursue this designation most commonly?

The most common pursuers are:

• Specialty pharmacies dispensing opioids for chronic pain, oncology, or post-surgical patients
• Pharmacy benefit managers overseeing opioid utilization management across large member populations
• Mail service pharmacies fulfilling high-volume controlled substance prescriptions
• Managed care health plans with formulary authority and opioid clinical management programs
• Patient care management organizations coordinating care for members with chronic pain or opioid use disorder
• Workers' compensation PBMs managing opioid utilization in injury populations

Is the Opioid Stewardship Designation required by law or payers?

The designation is voluntary — no state or federal law mandates it. However, payers, health systems, and state contracting authorities increasingly use voluntary designations as differentiators in contract awards, network inclusion, and preferred vendor decisions. As opioid stewardship regulatory expectations intensify across the healthcare system, voluntary designations that were once differentiators tend to become baseline expectations over time.

The Review Process

What does URAC review during the evaluation?

URAC reviewers evaluate operational compliance with each of the four standards — not just policy documentation. Evidence typically includes:

• Written policies and procedures aligned with URAC's interpretive information for each standard
• Staff training records demonstrating competency in opioid stewardship protocols
• Operational monitoring data — prescribing patterns, patient risk screening, utilization management records
• Escalation pathway documentation for identified opioid safety concerns
• Leadership governance records demonstrating executive accountability for opioid stewardship activities

URAC is evaluating whether the organization is actually operating compliant opioid stewardship programs — not whether it has drafted policies expressing an intention to do so.

Can we pursue the designation concurrently with our primary URAC accreditation?

Yes, and IHS recommends concurrent pursuit when your primary accreditation already requires clinical protocol and policy development. The marginal documentation effort for the designation is substantially lower when foundational infrastructure is being built for the primary accreditation. Sequential pursuit — adding the designation after the primary accreditation — is appropriate when the primary accreditation timeline is already under pressure. IHS advises on the optimal sequencing during the initial engagement.

How long does it take to obtain the designation?

When pursued concurrently with a primary URAC accreditation, the designation follows the primary program timeline — typically 9 to 18 months depending on the primary program and your organization's starting compliance posture. When pursued sequentially after an existing accreditation, the timeline is shorter because foundational documentation infrastructure is already in place. The primary variable is how long your organization needs to generate operational compliance evidence across the four standards.

What are the most common reasons organizations fail to achieve the designation?

IHS observes five recurring failure modes:

1. Treating it as a policy exercise. Policies exist, but monitoring data and training records do not. URAC reviews operational reality.
2. Inadequate leadership governance. No executive sponsor, no cross-functional ownership across pharmacy, clinical, and compliance functions.
3. Data collection gaps. No systematic monitoring of prescribing patterns, patient risk screening, or clinical adherence.
4. Misapplication of generic opioid stewardship frameworks. Joint Commission, AHRQ, and AHA opioid stewardship frameworks do not map directly to URAC's interpretive information. Applying the wrong framework produces policies that satisfy the spirit but not the letter of URAC's evaluation criteria.
5. Siloed documentation. Treating the designation as separate from the primary accreditation creates conflicting or redundant documentation that URAC reviewers flag.

Costs and Fees

How much do URAC Opioid Stewardship Designation fees cost?

URAC does not publicly publish its designation application and review fees. Contact URAC directly at urac.org for current fee schedules. IHS does not quote URAC fees on behalf of URAC — fee structures change and must be verified with URAC directly.

What does IHS charge for consulting?

IHS consulting engagement fees are scoped per engagement based on your organization's specific situation, primary accreditation context, complexity, and compliance gap severity. IHS does not publish standard rate cards. Contact us for a tailored proposal.

Working with IHS

How does IHS approach this engagement?

IHS begins with eligibility confirmation and a gap assessment across all four designation standards. We then provide policy templates and operational protocol frameworks aligned with URAC's interpretive information, monitor implementation, conduct mock reviews before the formal URAC submission, and provide RFI response support if URAC issues information requests during the review. Thomas G. Goddard, JD, PhD — former Chief Operating Officer and General Counsel of URAC — leads all URAC consulting engagements with authoritative knowledge of how URAC constructs and applies its standards.

Does IHS consult on the primary URAC accreditation and the designation together?

Yes. IHS routinely coordinates primary URAC accreditation engagements with concurrent Opioid Stewardship Designation pursuit. Integrated consulting ensures that opioid stewardship documentation builds on — rather than duplicates or contradicts — the primary accreditation evidence framework. See our consulting pages for URAC Specialty Pharmacy Accreditation and URAC PBM Accreditation.

Questions Not Answered Here?

Schedule a no-obligation consultation with IHS. We will assess your eligibility, clarify any open questions about the designation and its standards, and give you a clear path forward.

Schedule a Free Discovery Session